Liz Barrett, UroGen CEO, at the 2019 Forbes Healthcare Summit (Steven Ferdman/Getty Images)
August 27, 2020 09:27 AM EDTUpdated 10:09 AM
R&D

That pipeline Ab­b­Vie ac­quired in the $63B Al­ler­gan buy­out? It’s not do­ing so well

John Carroll

Editor & Founder

An­oth­er Al­ler­gan project picked up by Ab­b­Vie in their $63 bil­lion buy­out has turned sour.

Uro­Gen $URGN re­port­ed Thurs­day morn­ing that a Phase II …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times